Gold(I)-Catalyzed Cycloisomerization of 2-Fluoroalk-3-yn-1-ones
3-Fluoro-5-(4-methylphenyl)-2-phenylfuran (5a)[12]
[6] W. K. Hagmann, J. Med. Chem. 2008, 51, 4359–4369.
[7] Review: O. Serdyuk, A. Butin, V. Abaev, J. Fluorine
Chem. 2010, 131, 296–319.
[8] A. S. Cantrell, P. Engelhardt, M. Hçgberg, R. S. Jasku-
nas, N. G. Johansson, C. L. Jordan, J. Kangasmetsꢄ,
M. D. Kinnick, P. Lind, J. M. Morin Jr, M. A. Muesing,
R. Noreꢃn, B. ꢅberg, P. Pranc, C. Sahlberg, R. J. Ter-
nansky, R. T. Vasileff, L. Vrang, S. J. West, H. Zhang, J.
Med. Chem. 1996, 39, 4261–4274.
[9] See also: S. Arimitsu, G. B. Hammond, Synthesis of
gem-Difluorinated Heterocycles Using a Difluoropro-
pargyl Molecular Scaffold, in: Fluorinated Heterocycles,
(Eds.: A. A. Gakh, K. L. Kirk), ACS Symposium Series
1003; American Chemical Society, Washington, DC,
2009, pp 135–162.
To a solution of the crude 9 from the reaction above in di-
chloromethane (10 mL), chlorotriphenylphosphine gold(I)
(0.013 g, 0.025 mmol) and silver trifluoromethanesulfonate
(0.0065 g, 0.025 mmol) were added. The mixture was stirred
vigorously in the darkness (the flask was wrapped in Al foil)
for 10 min. The solvent was removed by rotary evaporation
the residue was purified by silica gel column chromatogra-
phy (hexanes) to give 5a as a white solid; yield: 0.120 g
(0.476 mmol, 95%), mp 93–958C; anal. calcd. for C17H13FO:
C 80.93, H 5.19; found: C 80.72, H 5.44; IR (KBr): n=2923,
1631, 1501, 1428, 1150, 821, 792, 668 cmÀ1; MS (EI): m/z=
252 (M+, 100%); 1H NMR (acetone-d6): d=7.80–7.70 (m,
4H), 7.52–7.45 (m, 2H), 7.35–7.25 (m, 3H), 7.00 (d, J=
0.7 Hz, 1H), 2.36 (s, 3H); 13C NMR (acetone-d6): d=151.7
(d, J=9.1 Hz), 151.6 (d, J=252.3 Hz), 139.3, 136.2 (d, J=
20.5 Hz), 130.5, 129.9, 129.8 (d, J=5.2 Hz), 128.4 (d, J=
2.2 Hz), 128.1 (d, J=1.2 Hz), 124.7, 124.2 (d, J=5.2 Hz),
99.7 (d, J=20.3 Hz), 21.4; 19F NMR (CDCl3): d=À162.0.
´
[10] E. Dvornikova, M. Bechcicka, K. Kamienska-Trela, A.
´
Krꢆwczynski, J. Fluorine Chem. 2003, 124, 159–168.
[11] M. Derenberg, P. Hodge, J. Chem. Soc. Chem.
Commun. 1971, 233–234.
[12] W. Xu, Q.-Y. Chen, Org. Biomol. Chem. 2003, 1, 1151–
1156.
Supporting Information
[13] Silyloxy-substituted b-fluorofurans are obtained via
1 H, 13C, and 19F NMR spectra for new fluorofurans 5 and
crystallographic tables for 5c are available as Supporting In-
formation.
metallation-silylation
of
3-fluorofuran-2(5H)-ones
formed as a result of acid-catalyzed cyclization of 2-flu-
ˇ
oroalk-2-enoates: a) K. Pomeisl, J. Kvicala, O. Paleta, J.
Fluorine Chem. 2006, 127, 1390–1397; b) K. Pomeisl, J.
ˇ
ˇ
Cejka, J. Kvicala, O. Paleta, Eur. J. Org. Chem. 2007,
5917–5925.
[14] S. Arimitsu, G. B. Hammond, J. Org. Chem. 2007, 72,
8559–8561.
[15] S. Arimitsu, J. M. Jacobsen, G. B. Hammond, J. Org.
Chem. 2008, 73, 2886–2889.
[16] a) H. L. Sham, D. A. Batebenner, J. Chem. Soc. Chem.
Commun. 1991, 1134–1135; b) P. Li, Z. Chai, G. Zhao,
S.-Z. Zhu, Synlett 2008, 2547–2551.
Acknowledgements
We are indebted to the donors of the Petroleum Research
Fund (ACS-PRF#46094) administered by the American
Chemical Society and to Oakland University and its Research
Excellence Program in Biotechnology for the support of this
research. The National Science Foundation (NSF) awards
(CHE-0821487 and CHE-0722547) are also acknowledged.
Y.L. is grateful for the Provostꢀs Graduate Student Research
Award. We are grateful to Dr. Robert Syvret (Air Products
and Chemicals) for the generous supply of Selectfluor.
[17] S. Arimitsu, G. B. Hammond, J. Org. Chem. 2006, 71,
8665–8668.
[18] A. Sniady, A. Durham, M. S. Morreale, A. Marcinek, S.
Szafert, T. Lis, K. R. Brzezinska, T. Iwasaki, T. Ohshi-
ma, K. Mashima, R. Dembinski, J. Org. Chem. 2008,
73, 5881–5889, and references cited therein.
[19] a) A. Sniady, A. Durham, M. S. Morreale, K. A. Wheel-
er, R. Dembinski, Org. Lett. 2007, 9, 1175–1178; b) For
heterocylization reactions leading to pyrroles see: P.
Wyre˛bek, A. Sniady, N. Bewick, Y. Li, A. Mikus, K. A.
Wheeler, R. Dembinski, Tetrahedron 2009, 65, 1268–
1275.
[20] a) A. Sniady, M. S. Morreale, K. A. Wheeler, R. Dem-
binski, Eur. J. Org. Chem. 2008, 3449–3452; b) A.
Sniady, K. A. Wheeler, R. Dembinski, Org. Lett. 2005,
7, 1769–1772; c) M. S. Rao, N. Esho, C. Sergeant, R.
Dembinski, J. Org. Chem. 2003, 68, 6788–6790.
[21] G. S. Lal, G. P. Pez, R. G. Syvret, Chem. Rev. 1996, 96,
1737–1756.
References
[1] J. R. Thomas, P. J. Hergenrother, Chem. Rev. 2008, 108,
1171–1224.
[2] N. Issaeva, P. Bozko, M. Enge, M. Protopopova,
L. G. G. C. Verhoef, M. Masucci, A. Pramanik, G. Seli-
vanova, Nat. Med. 2004, 10, 1321–1328.
[3] See, for example: a) X. Ming, W. Ju, H. Wu, R. R. Tid-
well, J. E. Hall, D. R. Thakker, Drug Metab. Dispos.
2009, 37, 424–430; b) M. M. Nyunt, C. W. Hendrix,
R. P. Bakshi, N. Kumar, T. A. Shapiro, Am. J. Trop.
Med. Hyg. 2009, 80, 528–535.
[22] Studies of product distribution for reactions of NF-type
reagents indicate a two-step mechanism via an electron
transfer with subsequent fluorine radical transfer: T.
Umemoto, S. Fukami, G. Tomizawa, K. Harasawa, K.
Kawada, K. Tomita, J. Am. Chem. Soc. 1990, 112,
8563–8575.
[4] E. P. Cormier, M. Das, I. Ojima, Approved Active Phar-
maceutical Ingredients Containing Fluorine, in: Fluorine
in Medicinal Chemistry and Chemical Biology, (Ed.: I.
Ojima), Wiley-Blackwell, Chichester, 2009, pp 525–
603.
[5] J.-P. Bꢃguꢃ, D. Bonnet-Delpon, Bioorganic and Medici-
nal Chemistry of Fluorine, John Wiley & Sons, New
York, 2008, pp 279–351.
[23] S. C. Wilkinson, R. Salmon, V. Gouverneur, Future
Med. Chem. 2009, 1, 847–863.
Adv. Synth. Catal. 2010, 352, 2761 – 2766
ꢀ 2010 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim
2765